Table 2.

Effect of recalculation of eGFR using the 2009 Chronic Kidney Disease Epidemiology Collaboration equation without a race-specific coefficient on screened and randomized participants in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation trial

VariableOriginalRecalculatedDifferenceNet Change Total No. (%)
Screened individuals (overall)
 n84928492
 Screening eGFR, ml/min per 1.73 m2, mean (SD)58 (22)57 (22)
 Screening eGFR group, no. (%)P<0.001
   eGFR≥90835 (10)808 (10)−27 (−0.3)
   eGFR≥60 to <902876 (34)2822 (33)−54 (−0.6)
   eGFR≥45 to <602007 (24)2015 (24)8 (0.1)
   eGFR≥30 to <452166 (26)2203 (26)37 (0.4)
   eGFR<30608 (7)644 (8)36 (0.4)
  eGFR≥90 or eGFR<30, ml/min per 1.73 m2, no. (%)1443 (17)1452 (17)9 (0.1)
Screened individuals (Black)
 n524524
 Screening eGFR, ml/min per 1.73 m2, mean (SD)57 (22)50 (19)
  Screening eGFR group, no. (%)P<0.001
   eGFR≥9046 (9)19 (4)−27 (−5)
   eGFR≥60 to <90174 (33)120 (23)−54 (−10)
   eGFR≥45 to <60141 (27)149 (28)8 (2)
   eGFR≥30 to <45117 (22)154 (29)37 (7)
   eGFR<3046 (9)82 (16)36 (7)
  eGFR≥90 or eGFR<30, ml/min per 1.73 m2, no. (%)92 (18)101 (19)9 (2)
Randomized individuals (overall)
 n44014401
 Screening eGFR, ml/min per 1.73 m2, mean (SD)a56 (16)56 (16)
  Screening eGFR group, no. (%)P<0.001
   eGFR≥90000
   eGFR≥60 to <901820 (41)1783 (41)−37 (−0.8)
   eGFR≥45 to <601278 (29)1286 (29)8 (0.2)
   eGFR≥30 to <451303 (30)1310 (30)7 (0.2)
   eGFR<30022 (0.5)22 (0.5)
  eGFR≥90 or eGFR<30, ml/min per 1.73 m2, no. (%)022 (0.5)22 (0.5)
Randomized individuals (Black)
 n224224
 Screening eGFR, ml/min per 1.73 m2, mean (SD)a56 (16)49 (14)
  Screening eGFR group, no. (%)P<0.001
   eGFR≥90000
   eGFR≥60 to <9089 (40)52 (23)−37 (−17)
   eGFR≥45 to <6073 (33)81 (36)8 (4)
   eGFR≥30 to <4562 (28)69 (31)7 (3)
   eGFR<30022 (10)22 (10)
 eGFR≥90 or eGFR<30, ml/min per 1.73 m2, no. (%)022 (10)22 (10)
  • a Means (SDs) were calculated as per 4397 randomized participants (4174 non-Black and 223 Black participants) with available data for screening eGFR. For four participants (three non-Black and one Black) with missing screening eGFR, screening eGFR group was assigned with the same category method reported in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation trial. Overall, two participants with missing screening eGFR were placed in the eGFR≥45- to <60-ml/min per 1.73 m2 category, and two participants with missing screening eGFR were placed in the eGFR≥30- to <45-ml/min per 1.73 m2 category. Among Black participants, one participant with missing screening eGFR was placed in the eGFR≥45- to <60-ml/min per 1.73 m2 category.